For placebo , golimumab 50 mg and golimumab 100 mg , respective adverse event incidences/100 pt-yrs ( 95 % CIs ) up to wk 160 were : 0.28 ( 0.01 to 1.56 ) , 0.30 ( 0.12 to 0.62 ) , 0.41 ( 0.23 to 0.69 ) for death ; 5.31 ( 3.20 to 8.30 ) , 3.03 ( 2.36 to 3.82 ) , 5.09 ( 4.36 to 5.90 ) for serious infection ; 0.00 ( 0.00 to 0.84 ) , 0.17 ( 0.05 to 0.44 ) , 0.35 ( 0.18 to 0.62 ) for tuberculosis ; 0.00 ( 0.00 to 0.84 ) , 0.13 ( 0.03 to 0.38 ) , 0.24 ( 0.10 to 0.46 ) for opportunistic infection ; 0.00 ( 0.00 to 0.84 ) , 0.00 ( 0.00 to 0.13 ) , 0.12 ( 0.03 to 0.30 ) for demyelination ; and 0.00 ( 0.00 to 0.84 ) , 0.04 ( 0.00 to 0.24 ) , 0.18 ( 0.06 to 0.38 ) for lymphoma .